Cooper Companies' Innovation Fuels Growth Amid Macro Headwinds

The Cooper Companies (COO) exhibits strong operational performance, achieving 14% adjusted EPS growth and expanding operating margins to 24.9% through product innovation in contact lenses and robust growth in its surgical portfolio. However, the company faces significant near-term headwinds, including a slowdown in its fertility segment, now projected for low-single-digit growth in fiscal 2025, along with channel inventory destocking pressures and potential tariff and FX risks impacting future earnings. Despite an estimated 10.1% bottom-line improvement over the next five years, COO shares have declined 20% year-to-date, underperforming the industry and broader market due to these macro and sector-specific challenges.

Analysis

The Cooper Companies (COO) presents a contrasting profile of solid operational execution against significant market headwinds, contributing to its substantial stock underperformance. The company delivered a 14% year-over-year increase in adjusted EPS and expanded its operating margin to 24.9% through disciplined cost management. Growth drivers remain robust in key segments, with MySight myopia products growing 35% and the PARAGARD IUD up 18%. However, these strengths are currently overshadowed by cyclical pressures, which helps explain the stock's 20% year-to-date decline. Key concerns include a material slowdown in the fertility segment, where fiscal 2025 growth expectations have been revised down to low-single-digits, and persistent channel inventory destocking in the contact lens market. Furthermore, forward-looking risks such as an expected $4 million tariff impact on fiscal 2025 cost of goods sold and a potential 3% EPS headwind in fiscal 2026 add to investor uncertainty.

Key Decisions for Investors

• Investors should weigh the company's strong operational execution, including its 14% EPS growth and margin expansion, against the clear near-term headwinds that are currently driving stock underperformance.
• Monitor upcoming earnings reports for any signs of stabilization in the fertility segment, as a recovery here from its downgraded low-single-digit growth forecast is a key potential catalyst for the stock.
• The disclosed $4 million tariff hit for fiscal 2025 and a potential 3% EPS headwind for fiscal 2026 should be factored into valuation models, as these external risks could continue to pressure margins.